Literature DB >> 6646238

A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.

M G Feenstra, C Sumners, J H Goedemoed, J B de Vries, H Rollema, A S Horn.   

Abstract

Several dopamine (DA) receptor agonists, notably N,N-dipropyl-2-aminotetralin analogues differing in the number and position of phenolic hydroxyl groups, were evaluated in model systems for pre- and postsynaptic dopaminergic activity. Apomorphine, piribedil and pergolide were included for comparison. All compounds inhibited the gamma-butyrolactone (GBL)-induced increase in DA concentrations in the rat striatum and olfactory tubercle, although a dose-dependency could not be demonstrated for one of the compounds, i.e. N,N-dipropyl-2-amino-5,6-dihydroxy-tetralin. In addition to the reversal of the DA-increase all compounds decreased the HVA and DOPAC levels in a dose-dependent manner, in much the same way as in normal, non GBL-pretreated rats. The potencies of the drugs to decrease HVA in normal rats and to inhibit the DA-increase and to decrease HVA in GBL-pretreated rats, both in the striatum and the olfactory tubercle were compared with each other and with the potencies to induce stereotyped behaviour. It may be concluded that (1) N,N-dipropyl-2-amino-7-hydroxytetralin shows the largest difference in activity in the biochemical and the behavioural models, suggesting a selective presynaptic activity. This was corroborated by the appearance of a marked hypomotility after low doses of this compound; (2) The potencies to decrease striatal HVA concentrations are generally somewhat different from the potencies to inhibit GBL-induced DA-increases, but appear to be comparable to the potencies to inhibit GBL-induced dihydroxyphenylalanine (DOPA)-increases; (3) There is no indication that the DA agonists in general are more potent at presynaptic receptors in the tubercle than in the striatum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6646238     DOI: 10.1007/BF00497015

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

1.  Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity.

Authors:  N E Andén; U Strömbom; T H Svensson
Journal:  Psychopharmacologia       Date:  1973

Review 2.  The hypotheses of different dopamine receptor mechanisms.

Authors:  B Costall; R J Naylor
Journal:  Life Sci       Date:  1981-01-19       Impact factor: 5.037

3.  Effect of dihydroxy-2-aminotetralin derivatives on dopamine metabolism in the rat striatum.

Authors:  M G Feenstra; H Rollema; A S Horn; D Dijkstra; C J Grol; B H Westerink; A Westerbrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-01       Impact factor: 3.000

4.  Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro.

Authors:  K Starke; W Reimann; A Zumstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

5.  Rapid concurrent automated fluorimetric assay of noradrenaline, dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 3-methoxytyramine in milligram amounts of nervous tissue after isolation on Sephadex G10.

Authors:  B H Westerink; J Korf
Journal:  J Neurochem       Date:  1977-10       Impact factor: 5.372

6.  Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate.

Authors:  M C Nowycky; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

7.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

8.  Estimation of the turnover of 3-methoxytyramine in the rat striatum by HPLC with electrochemical detection: implications for the sequence in the cerebral metabolism of dopamine.

Authors:  B H Westerink; S J Spaan
Journal:  J Neurochem       Date:  1982-02       Impact factor: 5.372

9.  Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.

Authors:  U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

10.  Postsynaptic dopamine agonist properties of TL-99 are revealed by yohimbine co-treatment.

Authors:  G Pastor; S Fallon; J J Welch; J M Liebman
Journal:  Eur J Pharmacol       Date:  1983-03-04       Impact factor: 4.432

View more
  11 in total

Review 1.  Retinal dopamine D1 and D2 receptors: characterization by binding or pharmacological studies and physiological functions.

Authors:  M Schorderet; J Z Nowak
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

2.  Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.

Authors:  R Depoortere; G Perrault; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

Review 3.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.

Authors:  H Rollema; M G Feenstra; C J Grol; M H Lewis; L Staples; R B Mailman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

5.  Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain.

Authors:  T Kling-Petersen; E Ljung; K Svensson
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist.

Authors:  A S Horn; P Tepper; J Van der Weide; M Watanabe; D Grigoriadis; P Seeman
Journal:  Pharm Weekbl Sci       Date:  1985-10-25

Review 7.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

8.  Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.

Authors:  D Lévesque; J Diaz; C Pilon; M P Martres; B Giros; E Souil; D Schott; J L Morgat; J C Schwartz; P Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

9.  Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.

Authors:  T B Mulder; J B de Vries; D Dijkstra; J W Wiechers; C J Grol; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

10.  The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.

Authors:  J C van Oene; J B de Vries; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.